In a South African trial, 340 babies born to HIV-infected mothers will receive either a new TB vaccine called MVA85A or a placebo at birth, with HIV-free infants getting a delayed BCG shot at eight weeks. This matters because BCG, the only licensed TB vaccine, can cause fatal complications in HIV-infected newborns. Yet HIV tests are unreliable until six weeks, by which time BCG has already been given at birth. More than a quarter of South African babies are born to HIV-positive mothers, and children in these households face the world’s highest TB rates. The trial tests whether MVA85A—a vaccine similar to the smallpox shot but with a TB protein added—can safely bridge that dangerous gap. If MVA85A proves safe and generates a strong immune response in newborns, the next step would be a larger trial testing whether it actually prevents TB in all infants, regardless of maternal HIV status. Success could reshape the global infant vaccination schedule, protecting children who currently receive either a risky or ineffective BCG shot. The findings would directly inform vaccine policy in high-burden countries, where TB kills hundreds of thousands of children each year.
View original technical description
BCG vaccine offers limited protection against lung TB in children. BCG vaccination is safe for most newborn babies, but may cause severe, often fatal, complications in babies with HIV infection, even with antiretroviral treatment (ART). The WHO recommends that BCG should not be given to babies known to be HIV infected. However, HIV testing is not accurate until 6 weeks of age, when BCG has already been given at birth. More than one quarter of South African babies were born to HIV infected mothers in 2009. South Africa has the highest annual TB rate in the world and children of HIV infected mothers are at especially high risk of TB. New TB vaccines are being developed and tested (http://www.stoptb.org/wg/new_vaccines/). MVA85A is a new TB vaccine, similar to the smallpox vaccine, but with a TB protein added. MVA85A vaccine has been shown to be safe and generates an immune response against TB in children and adults, including people with HIV infection. We have shown that if BCG vaccination is delayed for several weeks after birth, the immune response thought to be important for protection against TB is improved. Immunity is also improved if a new TB vaccine, such as MVA85A, is given several weeks after BCG. Some studies suggest that it does not matter for immunity whether BCG or the new vaccine is given first. We will test whether MVA85A vaccine can be given to babies at birth, at our experienced TB vaccine trial sites near Cape Town, South Africa, where rates of HIV infection and TB are high. This trial will test the safety and immunity of MVA85A vaccination at birth, compared to a dummy vaccination (placebo), in 340 babies of HIV infected mothers, followed up for one year. Only those babies proven not to have HIV infection would receive delayed BCG vaccine at 8 weeks of age. HIV infected babies would benefit by not receiving BCG and this is the reason for testing newborn MVA85A vaccination among infants of HIV infected mothers. If we show that newborn MVA85A vaccination has few side-effects and generates a good immune response against TB, we may proceed to test whether this new TB vaccine strategy actually prevents TB, among all infants, regardless of maternal HIV infection. These findings will be critically important for vaccine safety, and prevention of childhood TB, and may lead to key improvements in the global infant vaccination schedule.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know